Clinical Trial Update: Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity trial update for GSK's 10-valent pneumococcal conjugate vaccine has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Streptococcal

Drugs mentioned

• 10-valent pneumococcal conjugate vaccine (pneumococcal conjugate vaccine (10-valent))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED | Results posted: 2018-12-07